Hemoglobin Variability and Hyporesponsiveness: Much Ado About Something or Nothing?

Advances in Chronic Kidney Disease

Volumn 16, Issue 2, 2009, Pages 83-93

  Yee, Jerry ^a   Zasuwa, Gerard ^a   Frinak, Stanley ^a   Besarab, Anatole ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agent; Hyporesponsiveness; Iron deficiency; Sensitivity; Variability

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COMORBIDITY; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; ERYTHROCYTE LIFESPAN; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; IRON THERAPY; KIDNEY FAILURE; MALNUTRITION; PARATHYROID HORMONE BLOOD LEVEL; PHLEBOTOMY; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ANEMIA, IRON-DEFICIENCY; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS;

EID: 60149089001     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.12.003     Document Type: Article

References (65)

1. Bourne D.W.A. Parameter variability. Available at. http://www.boomer.org/c/p3/c19/c1903.html Accessed November 15, 2008
2. Costongs GM, Janson PC, Bas BM, et al: Short-term and long-term intra-individual variations and critical differences of clinical chemical laboratory parameters. J Clin Chem Clin Biochem 23:7-16, 10985
3. Lacson E., Ofshtun N., and Lazarus M. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41 (2003) 111-124
4. Berns J.S., Elzein H., Lynn R.I., et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64 (2003) 1514-1521
5. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
6. Fishbane S., and Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 (2005) 1337-1343
7. West R.M., Harris K., Gilthorpe M.S., et al. A description of the variability of patient responses in the control of renal anemia: Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients. J Am Soc Nephrol 18 (2007) 2371-2376
8. Brimble K.S., and Clase C.M. Hemoglobin variability in dialysis patients. J Am Soc Nephrol 18 (2007) 2218-2220
9. Yang W., Israni R.K., Brunelli S.M., et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18 (2007) 3164-3170
10. Brunelli S.M., Joffe M.M., Israni R.K., et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 777-782
11. Ross D.W., Ayscue L.H., Watson J., et al. Stability of hematologic parameters in healthy subjects. Intra-individual versus inter-individual variation. Am J Clin Pathol 90 (1988) 262-267
12. Dot D., Miró J., and Fuentes-Arderiu X. Within-subject biological variation of hematological quantities and analytical goals. Arch Pathol Lab Med 116 (1992) 825-826
13. Statland B.E., Winkel P., Harris S.C., et al. Evaluation of biologic sources of variation of leukocyte counts and other hematologic quantities using very precise automated analyzers. Am J Clin Pathol 69 (1978) 48-54
14. Cheung A.K., Daugirdas J., and Dwyer J. Seasonal variations (SV) in clinical and laboratory parameters in hemodialysis patients. J Am Soc Nephrol 10 (1999) 236A
15. Breiterman-White R. Hemoglobin variability: Managing inevitable changes in clinical status. Nephrol Nurs J 32 (2005) 549-552
16. Boudville N., Djurdjev O., Macdougall I., et al. Haemoglobin variability and association with erythropoietin stimulating agents (ESA) use and mortality in a chronic kidney disease (CKD) population: An international multicenter study. J Am Soc Nephrol 19 (2008) 322A abstr
17. Mohandas N., Kim Y.R., Tycko D.H., et al. Accurate and independent measurement of volume and hemoglobin concentration of individual red cells by light scattering. Blood 68 (1986) 506-513
18. Lew V.L., Raftos J.E., Soretto M., et al. Generation of normal human red cell volume, hemoglobin content, and membrane area distributions by "birth" or regulation?. Blood 86 (1995) 334-341
19. Ponder E., and Barreto D. The variation in the corpuscular hemoglobin concentration in the human red cell, as measured by densitometry. J Gen Physiol 39 (1955) 23-29
20. Rosenblit J., Abreu C.R., Szterling L.N., et al. Evaluation of three methods for hemoglobin measurement in a blood donor setting. Sao Paulo Med J 117 (1999) 108-112
21. Beutler E., and Waalen J. The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration?. Blood 107 (2005) 1747-1750
22. Izaks G.J., Westendorp R.G.J., and Knook D.L. The definition of anemia in older persons. JAMA 281 (1999) 1714-1717
23. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130 (1999) 461-470
24. Wu W.-C., Rathore S.S., Wang Y., et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 (2001) 1230-1236
25. Goodnough L.T., and Bach R.G. Anemia, transfusion, and mortality. N Engl J Med 345 (2001) 1272-1273
26. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients: A systematic review and meta-analysis. J Am Coll Cardiol 52 (2008) 818-827
27. Denny S.D., Kuchibhatla M.N., and Cohen H.J. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 119 (2006) 327-334
28. Guralnik J.M., Eisenstaedt R.S., Ferucci L., et al. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 104 (2004) 2263-2268
29. Ebben J.P., Gilbertson D.T., Foley R.N., et al. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1 (2006) 1205-1210
30. Gilbertson D.T., Ebben J.P., Foley R.N., et al. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3 (2008) 133-138
31. Besarab A. Treatment of anemia in dialysis patients. In: Henrich W.L. (Ed). Principles and Practice of Dialysis (2002), Williams and Wilkins, Philadelphia, PA, Lippincott 487
32. Yaqub M.S., Leiser J., and Molitoris B.A. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 21 (2008) 390-396
33. Kruskall M.S., Horowitz G.L., and Smoller B.R. Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes. Am J Clin Pathol 91 (1989) 701-703
34. Hsu C.Y., McCulloch C.E., and Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13 (2002) 504-510
35. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000) 530-538
36. DeVita M.V., Frumkin D., Mittal S., et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 60 (2003) 335-340
37. Besarab A., and Yee J. An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10 (1999) 2029-2043
38. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to iv iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 18 (2007) 975-984
39. Gregory C.J. Erythropoietin sensitivity as a differentiation marker in the hemopoietic system: Studies of three erythropoietic colony responses in culture. J Cell Physiol 89 (1976) 289-301
40. Uehlinger D.E., Gotch F.A., and Sheiner L.B. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51 (1992) 76-89
41. National Kidney Foundation. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 (2006) S1-S145
42. Tsai A., and Berns J.S. Anemia management. In: Byhan-Gray L.D., Chertow G.M., and Burrowes J.D. (Eds). Nutrition in Kidney Disease (2008), Humana Press, Totawa 337-356
43. Manley H.J., McClaran M.L., Overbay D.K., et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 41 (2003) 386-393
44. Manley H.J., Garvin C.G., Drayer D.K., et al. Medication prescribing patterns in ambulatory haemodialysis patients: Comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant 19 (2004) 1842-1848
45. Milman N. Prepartum anaemia: Prevention and treatment. Ann Hematol 87 (2008) 949-959
46. Gunnell J., Yeun J.Y., Depner T.A., et al. Acute-phase response predicts erythropoietin resistance in hemodialysis patients. Am J Kidney Dis 33 (1999) 63-72
47. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated?. Nephrol Dial Transplantation 17 (2002) 33-38
48. Vyoral D., and Petrak J. Hepcidin: A direct link between iron metabolism and immunity. Int J Biochem Cell Biol 37 (2005) 1768-1773
49. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
50. Yee J. Diabetic kidney disease: Chronic kidney disease and diabetes. Diabetes Spectrum 21 (2008) 8-11
51. O'Mara N.B. Anemia in patients with CKD. Diabetes Spectrum 21 (2008) 12-19
52. LiVecchi M., Fuiano G., Francesco M., et al. Prevalence and severity of anemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency. Nephron Clin Pract 105 (2007) c62-c67
53. Gansevoort R.T., Vaziri R.D., and de Jong P.E. Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Am J Kidney Dis 28 (1996) 274-277
54. United States Renal Data Survey (USRDS) 2008 Annual Report, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD, April 2008: Morbidity and Mortality: All-cause hospitalization. Chapter 3, p 5. Available at: http://www.usrds.org/2008/pdf/V1_03_2008.pdf?zoom_highlight=hospitalization+infection. Accessed November 14, 2008
55. Nassar G.M., Fishbane S., and Ayus J.C. Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int 61 (2002) S49-S54
56. Rao D.S., Shih M.-S., and Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328 (1993) 171-175
57. Tonelli M., Blake P.G., and Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 47 (2001) 82-85
58. Casadevall N., Eckardt K.U., and Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 16 (2005) 567-569
59. Klauder D.S., and Petering H.G. Anemia of lead intoxication: A role for copper. J Nutr 107 (1977) 1779-1785
60. Schwartz J., Landrigan P.J., Baker E.L., et al. Lead-induced anemia: Dose-response relationships and evidence for a threshold. Am J Public Health 80 (1990) 165-168
61. Abreo K., Glass, and Sella M. Aluminum inhibits hemoglobin synthesis but enhances iron uptake in friend erythroleukemia cells. Kidney Int 37 (1990) 677-681
62. Tarng D.-C., and Huang T.-P. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: Role of aluminum toxicity. Am J Nephrol 18 (1998) 1-8
63. Agarwal R., Davis J.L., and Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 98-104
64. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-A dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
65. Kilpatrick R.D., Critchlow C.W., Fishbane S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1077-1083